AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$SYRE

Burrows Scott L sold $2.3M of SYRE

Burrows Scott L (Chief Financial Officer) sold 25,732 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $88.75 ($86.25–$89.35, $2.28M total) across 5 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burrows Scott L
Published Sep 4, 2026, 1:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SYRE
Bearish
medium confidence
Mentioned
$SYRE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYREBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short‑term positioning.

02

Market read

Primary disclosure of a significant insider sale; modest trading relevance.

03

What to watch

Potential upcoming clinical data releases could offset sell pressure.

Relevance 5/10Novelty 5/10Timing: filed 2026-09-03, effective 2026-09-01/02

Background

Form 4 filings disclose insider transactions; a CFO sale is noteworthy for traders monitoring insider activity.

Company-level read

Ticker impact

$SYREBearishMedium confidence
Context

CFO Burrows Scott L sold 25,732 shares for $2.28M via a 10b5‑1 plan, reducing his stake to 79,762 shares.

Expected impact

Modest downward pressure over the next few days.

Evidence & confidence

Large insider sale by CFO, executed through a pre‑arranged plan, suggests possible cashing out; however, the sale size is modest relative to market cap and may be routine.

Market effects

Sector

May slightly affect biotech sector sentiment if similar insider sales occur.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    Spyre Therapeutics, Inc.

    Biotech firm developing therapies; ticker SYRE.

  • Individual
    Burrows Scott L

    Chief Financial Officer of Spyre Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SYRE insider trading history →

Related articles

SEP 17
$SYREMedAI 9/10

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

insidermonkey.com2 min
SEP 11
$SYREMedAI 8/10

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

insidermonkey.com2 min
AUG 27
$SYREMedAI 8/10

Top Biotechnology Stock Pick from Guggenheim

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

investing.com2 min
AUG 26
$SYREHighAI 8/10

Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

investing.com2 min